Domo signs strategic collaboration agreement with AWS for AI solutions
In a recent transaction reported to the Securities and Exchange Commission, Steve Forte, the Executive Vice President and Chief Financial Officer of Repare Therapeutics Inc . (NASDAQ:RPTX), sold 6,884 common shares of the company. The shares were sold on March 12 at a price of $1.14 each, totaling approximately $7,847. The transaction occurs as RPTX trades near its 52-week low of $1.06, with the stock down about 78% over the past year. According to InvestingPro analysis, the company currently holds more cash than debt on its balance sheet.
Following this transaction, Forte holds 54,786 shares in the company. The sale was made to satisfy tax withholding obligations related to the vesting and settlement of restricted stock units, as indicated in the filing. This transaction did not represent a discretionary sale by Forte. InvestingPro data reveals the company is quickly burning through cash, though it maintains strong liquidity with a current ratio of 6.77. Get access to 10+ additional InvestingPro Tips and comprehensive financial metrics to make better-informed investment decisions.
In other recent news, Repare Therapeutics reported a net loss of $28.7 million, or $0.67 per share, for the fourth quarter of 2024, and a total net loss of $84.7 million, or $2.00 per share, for the entire year. The company is focusing on three Phase 1 trials, with results anticipated in 2025, and has reduced its workforce by about 75% to extend its financial runway. Analysts at H.C. Wainwright adjusted their price target for Repare Therapeutics, lowering it from $10.00 to $5.00, while maintaining a Buy rating, citing changes in their financial model and future projections. Stifel analysts also revised their price target from $4.00 to $3.00, yet upheld a Buy rating, noting optimism for the potential of RP-3467 in combination with olaparib. Conversely, Bloom Burton & Co. downgraded Repare Therapeutics from Buy to Hold, due to the absence of human data for the company’s drugs RP-3476 and RP-1664. Repare Therapeutics has approximately $152.8 million in cash, which is expected to sustain operations into late 2027. The company’s strategic shift towards early-stage assets, such as RP-1664 and RP-3467, reflects its current focus in the precision oncology sector. Investors are watching closely for upcoming trial results, which are crucial for the company’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.